For research use only. Not for therapeutic Use.
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity[1][2][3].
Cagrilintide (compound 23) (0.1, 1, 3, 10, 30 nmol/kg; s.c.) reduces food intake in the rat[2].
Cagrilintide (10 nmol/kg; i.v. or s.c.) shows good pharmacokinetic parameters[2].
| Catalog Number | I043267 |
| CAS Number | 1415456-99-3 |
| Molecular Formula | C194H312N54O59S2 |
| Purity | ≥95% |
| Reference | [1]. Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther. 2021 Jun;377(3):417-440. [2]. Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021 Aug 12;64(15):11183-11194. [3]. Dehestani B, et al. Amylin as a Future Obesity Treatment. J Obes Metab Syndr. 2021 Dec 30;30(4):320-325. |
